[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stable-coronary-artery-disease-cad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stable-coronary-artery-disease-cad":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100607945","phase-3-comparing-high-and-low-dose-aspirin-with-dual-antiplatelet-therapy-for-three-months-using-prasugrel-and-aspirin-following-coronary-artery-bypass-grafting-optimus-cabg-trial-100607945",false,"NCT07195149","Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)","OPTIMUS-CABG","Inclusion Criteria:\n\nA. Baseline (preoperative) inclusion criteria\n\n1. Age \\>18 years\n2. Primary isolated CABG patients with stable coronary artery disease (chronic coronary syndrome) planned for at least 2 grafts. Coronary artery disease will be defined as a stenosis ≥ 70% based on coronary angiography, a FFR value ≤ 0.80 or iFr value ≤0.89; a left main diameter stenosis ≥ 50%, left main IVUS MLA value ≤ 6 mm2, or equivalent OCT measurements will also be considered.\n3. Ability to comply with all study procedures and follow-up procedures\n4. Signed Informed Consent to participate in the study.\n\nB. Operative inclusion criteria:\n\n1. Intraoperative graft evaluation using transit time flow measurement in all grafts, normal flow in any graft is defined as mean graft flow \\> 15 mL\u002Fmin with Pulsatility Index \\\u003C 5\n2. Left anterior descending artery grafted with internal thoracic artery\n3. No intraoperative decision for hybrid revascularization due to incomplete revascularization (Percutaneous coronary intervention (PCI) of the ungrafted vessel)\n4. No endarterectomy of the grafted vessel performed\n5. Patient did not have any additional unplanned procedure (Ex. LAAC, Ablation, valve intervention, aortic intervention)\n\nExclusion Criteria:\n\nA. Baseline (preoperative) exclusion criteria:\n\n1. Cardiogenic shock\n2. Patients with recent acute coronary syndrome (ACS) (\\\u003C12 months)\n3. Single vessel CABG\n4. Patients with preoperative atrial fibrillation\n5. Dialysis\n6. Thrombocytopenia (platelet count \\\u003C 100 000 platelets\u002FuL)\n7. Anemia (Hemoglobin level \\\u003C 10 g\u002FdL)\n8. Severe liver failure Child-Pugh classification \\>4\n9. Known, active infections with HIV, HBV, HCV, tuberculosis\n10. Active malignant disease or history of malignancy within the past 5 years\n11. Indication for DAPT (e.g. recent PCI or ACS or recent stents of peripheral arteries)\n12. Indication for oral anticoagulant treatment 13 Indications for the use of methotrexate at a dose of 15 mg\u002Fweek or more\n\n14\\. Any contraindication for prasugrel or ASA 15. Planned additional cardiac or non-cardiac surgery within 12 months 16. Non-cardiac co-morbidity with life expectancy less than 12 months 17. History of any bleeding complications due to the use of DAPT 18. History of intracranial bleeding 19. History of gastro-intestinal bleeding 20. Pregnancy or breastfeeding 21. Lack of compliance with the use of a highly effective method of birth control 22. Planned coronary endarterectomy 23. Severe impaired renal function (eGFR \\\u003C40mL\u002Fmin\u002F1.73 m2).\n\nB. Postoperative and prior randomization exclusion criteria:\n\n1. Perioperative cardiogenic shock\n2. Intraoperative death or death prior randomization\n3. Myocardial infarction within 12-24 hours following CABG or prior randomization\n4. Ischemic or hemorrhagic stroke within 12-24 hours following CABG or prior randomization\n5. Any postoperative complication that may increase patients' risk with DAPT\n6. Atrial Fibrillation prior randomization\n7. Gastro-intestinal bleeding prior randomization","ALL","18 Years",{"count":19,"type":20},1703,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to compare the effect of prasugrel plus low-dose aspirin versus high dose aspirin alone (300mg) and versus low dose aspirin alone (75 mg) in patients with chronic coronary disease undergoing coronary artery bypass grafting.",[26,27],"Chronic Coronary Syndrome","Stable Coronary Artery Disease CAD",[29,30,31,32,33,34,35],"DAPT","CABG","Prasugrel","Aspirin","CCS","Chronic coronary syndrome","Stable coronary artery disease","RECRUITING","2026-06-04",{"date":39,"type":40},"2026-06-05","ACTUAL",{"date":42,"type":40},"2025-11-25",{"date":44,"type":20},"2030-11-30",{"name":46,"class":47},"Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.","OTHER",18,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100619231","helium-free-magnetocardiography-guided-therapy-for-stable-coronary-artery-disease---a-randomized-controlled-trial-100619231","NCT07341932","Helium-free Magnetocardiography Guided Therapy for Stable Coronary Artery Disease - A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender.\n2. Patients with stable coronary artery disease (CAD).\n3. Coronary computed tomography angiography (CCTA) shows at least one major coronary vessel (diameter ≥2.5 mm) with 50-90% stenosis. Patients with 50-69% stenosis must have typical or atypical angina; for those with 70-90% stenosis, the presence of chest pain symptoms is not required.\n\n   \\*Note: Chest pain is characterized by the following three features:\\* \\*(1) Chest discomfort lasting less than 15 minutes;\\* \\*(2) Precipitated by physical exertion or emotional stress;\\* \\*(3) Relieved by rest or nitrates.\\* \\*Based on these, angina is classified as:\\*\n   * \\*Typical angina: all 3 features are present;\\*\n   * \\*Atypical angina: 2 features are present;\\*\n   * \\*Non-anginal chest pain: 1 or no feature is present.\\*\n4. Willing to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Previous myocardial infarction, PCI, CABG, or coronary angiography indicating stenosis ≥50% in a major vessel.\n2. CCTA indicating left main coronary artery stenosis \\>50% and\u002For three-vessel disease.\n3. History of cardiac dysfunction (≥ NYHA Class III), severe congenital heart disease, valvular heart disease, or cardiomyopathy.\n4. Complex arrhythmias, such as frequent atrial premature beats, ventricular premature beats, atrial fibrillation, atrial flutter, etc.\n5. History of metal implant placement (including mechanical valves, pacemakers, orthopedic internal fixation plates, drug pumps, etc.).\n6. Claustrophobia.\n7. Severe thoracic deformity.\n8. Active bleeding.\n9. Any disease with an expected survival of less than 1 year.\n10. Completion of any of the following tests prior to enrollment: exercise ECG, stress echocardiography, stress SPECT, or stress CMR.\n11. Any other condition where the investigator considers the patient unsuitable for this study.","80 Years",{"count":57,"type":20},1312,[59],"NA","This rigorously designed randomized controlled trial aims to investigate whether Magnetocardiography (MCG) can optimize the clinical pathway, improve quality of life, and reduce healthcare costs in patients with stable coronary artery disease (SCAD) within real-world clinical settings, thereby generating evidence for the future application of MCG in clinical decision-making pathways.\n\nStable CAD patients with at least one major coronary vessel showing 50%-90% stenosis on coronary CTA will be enrolled based on predefined criteria. Stratified by study center and using a central web-based randomization system, participants will be allocated in a 1:1 ratio to either the \\*\\*MCG-guided group\\*\\* (where treatment recommendations for invasive coronary angiography \\[ICA\\] or optimal medical therapy are based on MCG results) or the \\*\\*conventional management group\\*\\* (where treatment strategy is based on stenosis severity, pre-test probability, and functional test results).\n\nThe study will proceed with the following evaluations:\n\n1. Compare the proportion of patients with non-obstructive coronary artery disease on planned ICA performed within 90 days between the two groups, testing the hypothesis that this proportion is lower in the MCG-guided group.\n2. Conduct telephone follow-ups at 90 days, 6 months, and 12 months post-enrollment to compare between-group differences in the rate of Major Adverse Cardiovascular Events (MACE), Seattle Angina Questionnaire (SAQ) scores, and total healthcare expenditures during the follow-up period.",[27],[63,64,65],"Stable coronary artery disease CAD","MCG","Randomized Controlled Trial","2026-04-01",{"date":68,"type":40},"2026-04-02",{"date":70,"type":40},"2026-03-17",{"date":72,"type":20},"2027-12-01",{"name":74,"class":47},"Beijing Anzhen Hospital",5]